DK549189A - Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge - Google Patents

Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge

Info

Publication number
DK549189A
DK549189A DK549189A DK549189A DK549189A DK 549189 A DK549189 A DK 549189A DK 549189 A DK549189 A DK 549189A DK 549189 A DK549189 A DK 549189A DK 549189 A DK549189 A DK 549189A
Authority
DK
Denmark
Prior art keywords
disease
alzheimer
medicinals
galanthamine
analogue
Prior art date
Application number
DK549189A
Other languages
English (en)
Other versions
DK175839B1 (da
DK549189D0 (da
Inventor
Bonnie Davis
Madeleine Joullie
Original Assignee
Bonnie Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonnie Davis filed Critical Bonnie Davis
Publication of DK549189D0 publication Critical patent/DK549189D0/da
Publication of DK549189A publication Critical patent/DK549189A/da
Application granted granted Critical
Publication of DK175839B1 publication Critical patent/DK175839B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Processing Of Meat And Fish (AREA)
DK198905491A 1987-05-04 1989-11-03 Forbindelser af typen 6H-benzfuro[3a,3,-ef][2]benzazepin samt anvendelse af disse til behandling af Alzheimer's syge DK175839B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4652287A 1987-05-04 1987-05-04
US4652287 1987-05-04
PCT/US1988/001542 WO1988008708A1 (en) 1987-05-04 1988-05-04 Compounds for the treatment of alzheimer's disease
US8801542 1988-05-04
CA569641 1988-06-16
CA000569641A CA1338326C (en) 1987-05-04 1988-06-16 Compounds for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
DK549189D0 DK549189D0 (da) 1989-11-03
DK549189A true DK549189A (da) 1990-01-03
DK175839B1 DK175839B1 (da) 2005-03-21

Family

ID=42046403

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198905491A DK175839B1 (da) 1987-05-04 1989-11-03 Forbindelser af typen 6H-benzfuro[3a,3,-ef][2]benzazepin samt anvendelse af disse til behandling af Alzheimer's syge

Country Status (10)

Country Link
EP (1) EP0363415B1 (da)
JP (1) JP2755403B2 (da)
KR (1) KR100195399B1 (da)
AT (1) ATE411026T1 (da)
AU (1) AU632458B2 (da)
CA (1) CA1338326C (da)
DE (1) DE3856594D1 (da)
DK (1) DK175839B1 (da)
FI (1) FI102756B1 (da)
WO (1) WO1988008708A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
CZ295528B6 (cs) * 1994-10-21 2005-08-17 Sanochemia Pharmazeutika Ag Způsob výroby derivátů 4a,5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepinu
AT401058B (de) * 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
GB9506843D0 (en) 1995-04-03 1995-05-24 Chiroscience Ltd Oxidative process and products thereof
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519267D0 (en) * 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU1738800A (en) * 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
JP2003516947A (ja) 1999-12-10 2003-05-20 デイビス、ボニー ニコチン様物質受容体のモジュレーターとしてのガランタミンおよびリコラミンの類似物
DE50101827D1 (de) 2000-03-31 2004-05-06 Sanochemia Pharmazeutika Ag Wi Neue derivate und analoga von galanthamin
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
ES2463715T3 (es) 2008-04-14 2014-05-29 Neurodyn Life Sciences Inc. Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
TW201018694A (en) 2008-09-29 2010-05-16 Abbott Lab Indole and indoline derivatives and methods of use thereof
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN104853755B (zh) 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673177A (en) * 1970-05-04 1972-06-27 American Cyanamid Co Substituted 4-(anilinomethylene)-3-galanthamaninones
PL122665B1 (en) * 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
NL8800350A (nl) * 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.

Also Published As

Publication number Publication date
ATE411026T1 (de) 2008-10-15
WO1988008708A1 (en) 1988-11-17
JP2755403B2 (ja) 1998-05-20
EP0363415A1 (en) 1990-04-18
FI102756B (fi) 1999-02-15
AU1808488A (en) 1988-12-06
FI102756B1 (fi) 1999-02-15
EP0363415A4 (en) 1993-03-17
DE3856594D1 (de) 2008-11-27
DK175839B1 (da) 2005-03-21
CA1338326C (en) 1996-05-14
KR100195399B1 (ko) 1999-06-15
EP0363415B1 (en) 2008-10-15
AU632458B2 (en) 1993-01-07
FI895213A0 (fi) 1989-11-02
JPH02503794A (ja) 1990-11-08
KR890701107A (ko) 1989-12-19
DK549189D0 (da) 1989-11-03

Similar Documents

Publication Publication Date Title
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
NO892270D0 (no) Fremgangsmaate for fremstilling av preparater for anvendelse ved behandlingen av alkoholisme.
NO911952L (no) Behandling av tilstander og sykdommer samt midler derfor.
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
FI962557L (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
FI900501A0 (fi) Säiliön viimeistelyn tarkastus
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
NO892505L (no) Behandling av vandige dispersjoner.
NO922136D0 (no) Anvendelse av gibberelliner for behandling av prostatitisog psoriasis
DK325289D0 (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ATE142503T1 (de) Arzneimittelzubereitung bei der behandlung von tonsillitis
DK131188D0 (da) 3-(2-halogenalkyl)-1,4-oxathiiner og 2(2-halogenalkyl)-1,4-dithiiner, samt farmaceutiske praeparater indeholdende disse til behandling af leukaemi og tumorer
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
SE8900564D0 (sv) Novel medicinal use
NO920524L (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
SE8600655D0 (sv) Sett och anleggning for sterilisering
ATE89727T1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.
DK585389A (da) Praeparat til behandling af hudsygdomme samt anvendelse af artemisinin og derivater heraf til fremstilling af et saadant praeparat

Legal Events

Date Code Title Description
PUP Patent expired